



Pergamon

Synthesis and Biological Evaluation of 2,8-Disubstituted 9-Benzyladenines: Discovery of 8-Mercaptadenines as Potent Interferon-Inducers

Kosaku Hirota,* Kazunori Kazaoka and Hironao Sajiki

Laboratory of Medicinal Chemistry, Gifu Pharmaceutical University, 5-6-1 Mitahora-higashi, Gifu 502-8585, Japan

Received 24 February 2003; accepted 3 April 2003

Abstract—Recently, we have identified 9-benzyl-8-hydroxyadenines bearing an appropriate substituent (a butoxy, propylthio or butylamino group) at the 2-position as potent interferon (IFN)-inducers. Herein we report the design, synthesis, and IFN-inducing activity of 8-substituted 9-benzyladenines possessing such an appropriate substituent at the 2-position. Introduction of the appropriate substituent into the 2-position of the adenine nucleus gave rise to expression of the activity even in 9-benzyladenines bearing no hydroxyl group at the 8-position. An amino group at the 6-position and a hydroxyl or thiol group carrying an acidic proton at the 8-position are required to express excellent IFN-inducing activity. 9-Benzyl-2-butoxy-8-mercaptadenine (**9**) indicated the most potent activity with MEC of 0.001 μ M.

© 2003 Elsevier Science Ltd. All rights reserved.

Introduction

Hepatitis C virus (HCV) is a major cause of acute hepatitis and chronic liver disease, including cirrhosis and liver cancer. Globally, an estimated 170 million persons are chronically infected with HCV and 3–4 million persons are newly infected each year.¹ It has been a serious problem of HCV infection that the proportion of progression of hepatitis C to cirrhosis, liver failure, and liver cancer over a long period is very high.

The major therapeutic option of HCV carriers is interferon (IFN). Various clinical trials have been conducted to optimize IFN treatment of HCV-infected patients.² However, administration of recombinant IFN frequently induces neutralizing antibodies, which diminish the antiviral activity of IFN.³ Furthermore, the administration of IFN by intramuscular or subcutaneous injection causes severe pain and irritation at the site of injection. The cost of IFN therapy is also very high because of the inordinately expensive IFN preparations. To avoid such drawbacks, the development of an IFN inducer, which enhances the release of endogenous IFN by oral administration, has been ardently desired for a long time.

Various compounds possessing IFN-inducing activity have been hitherto reported.⁴ Since tilorone was reported as an IFN inducer,⁵ a variety of low-molecular-weight compounds including BL-20803,⁶ atabrine,⁷ CP-28888,⁸ ABMP,⁹ DRB,¹⁰ 10-carboxymethyl-9-acridone,¹¹ broprimine¹² and imiquimod^{13,14} have been reported as IFN inducers. Among them, imiquimod, which is clinically used in the USA for treatment of exophytic warts caused by the human papillomavirus, is especially a potent IFN inducer. However, its serious side-effects such as vomiting and hepatopathy found during the clinical trial stage forced abandonment of its further development as a chemotherapy drug for hepatitis C. Subsequently, imiquimod analogues such as R-842 (a hydroxylated metabolite of imiquimod)¹⁵ and resiquimod^{14,16} were found to be more effective IFN inducers than imiquimod (Fig. 1). However, no IFN inducer has yet been clinically employed for the treatment of hepatitis C.

Recently, we found 9-benzyl-8-hydroxyadenine (**1**) possessing an IFN-inducing activity as a lead compound in our first screening¹⁷ and its substituent modifications at the 2-, 6- and 9-positions were conducted to investigate structure–activity relationships for IFN-inducing activity.^{18,19} Consequently, it was found that the introduction of an appropriate chain substituent at the 2-position remarkably increases the activity. Among various 2-substituted 9-benzyl-8-hydroxyadenines,

*Corresponding author. Tel.: +81-58-237-8572; fax: +81-58-237-5979; e-mail: hirota@gifu-pu.ac.jp




Figure 1. Some advanced low-molecular-weight interferon inducers.

2-butoxy (**2**), 2-propylthio (**3**) and 2-butylamino (**4**) analogues indicated potent IFN-inducing activity.¹⁷ On the basis of the results mentioned above, our attention was directed to the chemical modification at the 8-position of 9-benzyladenines possessing a substituent having considerable influence on the activity such as a butoxy, propylthio or butylamino group at the 2-position. In this report, we describe the synthesis and evaluation of 8-substituted 9-benzyladenines (**A**) carrying an appropriate substituent at the 2-position as shown in **Figure 2**. In addition, in order to examine the importance of the 6-amino group, some 6-substituted 9-benzyl-8-hydroxypurines possessing such a chain substituent at the 2-position were synthesized and the IFN-inducing activity was evaluated.

Chemistry

First, synthesis of several 8-substituted 9-benzyl-2-butoxyadenines, whose 2-butoxy substituent induces the highest IFN-inducing activity in the 9-benzyl-8-hydroxyadenine series,¹⁷ was attempted. Most of the 8-substituted 9-benzyl-2-butoxyadenines were prepared from the corresponding 8-bromoadenine (**5**)¹⁸ as shown in **Scheme 1**. 8-Unsubstituted 9-benzyl-2-butoxyadenine (**6**) was prepared in 94% yield by hydrogenolysis of the 8-bromo group using a Pd/C catalyst in the presence of triethylamine. 8-Methoxy analogue (**7**) was prepared by nucleophilic substitution of **5** with sodium methoxide as previously reported.¹⁸ The synthesis of 8-methyl (**8**) and 8-mercapto (**9**) derivatives was achieved according to the usual methods.^{20,21} Cross-coupling of **5** with trimethylaluminum using a palladium catalyst²⁰ gave 8-methyladenine (**8**) in 96% yield, and refluxing of **5** and thiourea in ethanol²¹ afforded 8-mercaptoadenine (**9**) in 86% yield. Subsequently, **9** was selectively *S*-methylated with methyl iodide in the presence of potassium carbonate to give 8-methylthio analogue (**10**) in 88% yield. 8-Chloro analogue (**14**) was prepared from 5-amino-1-benzyl-4-cyanoimidazole (**11**)²² by the following three steps: chlorination of **11**, cyclization of **12** with urea and selective *O*-butylation of **13** (**Scheme 2**).







Figure 2. Strategy for structure-optimization of 9-benzyladenines.



Scheme 1. Reagents and conditions: (a) 10% Pd/C, (C₂H₅)₃N, H₂, CH₃OH, rt (94%); (b) ref 18; (c) Al(CH₃)₃, Ph₃P, PdCl₂, THF, reflux (96%); (d) H₂NCSNH₂, C₂H₅OH, reflux (86%); (e) CH₃I, K₂CO₃, DMF, rt (88%).



Scheme 2. Reagents and conditions: (a) NCS, THF, rt (87%); (b) H₂NCONH₂, neat (78%); (c) C₄H₉Br, K₂CO₃, DMF, rt (66%).




Scheme 3. Reagents and conditions: (a) C₃H₇CHO, NaBH₃CN, CH₃OH, rt (**16**: 84%, **18**: 85%).


Some 2-butylaminoadenine derivatives were also prepared, in which the synthetic methods of 8-unsubstituted (**16**) and 8-methoxy (**18**) analogues are illustrated in **Scheme 3**. 2-Amino-9-benzyladenine (**15**), which was easily prepared by the cyclization of imidazole **11**²² with guanidine, was treated with butyraldehyde in the presence of sodium cyanoborohydride

to afford the desired 9-benzyl-2-butylaminoadenine (**16**) via regioselective reductive alkylation.¹⁸ Similarly, the synthesis of 9-benzyl-2-butylamino-8-methoxyadenine (**18**) was carried out by reductive alkylation of 2-amino-9-benzyl-8-methoxyadenine (**17**), which was prepared by cyclization of 5-amino-1-benzyl-2-bromo-4-cyanoimidazole¹⁸ with guanidine and subsequent methanolysis of the 8-bromo group of the resulting 2-amino-9-benzyl-8-bromoadenine. The synthetic sequence of 8-mercaptoadenine (**22**) is shown in Scheme 4. 2-Mercaptoimidazole (**20**), which is a key intermediate for the preparation of **22**, was synthesized by treatment of aminomalononitrile with benzyl isothiocyanate and subsequent known ring-transformation²³ of the resulting thiazole (**19**) into imidazole (**20**) in alkali medium. Cyclization of **20** with guanidine gave 8-mercaptoadenine (**21**), which was selectively alkylated at the 2-amino group to yield the expected 9-benzyl-2-butylamino-8-mercaptoadenine (**22**). On the other hand, cyclization of thiazole **19** with guanidine did not give thiazolo[5,4-*d*]pyrimidine (**B**), but 8-mercaptoadenine **21** in 76% yield. This reaction would involve the ring-transformation caused by the basicity of guanidine.

Preparation of 9-benzyl-2-butylamino-8-hydroxypurine (**25**) was performed as shown in Scheme 5. Removal of



Scheme 4. Reagents and conditions: (a) PhCH₂NCS, THF, 40 °C, (86%); (b) 5% Na₂CO₃, reflux (84%); (c) H₂NC(NH)NH₂·HCl, NaOC₂H₅, C₂H₅OH, reflux (from **19**: 76%, from **20**: 69%); (d) C₃H₇CHO, NaBH₃CN, CH₃OH, rt (72%).




Scheme 5. Reagents and conditions: (a) Raney Ni, NH₄OH, CH₃OH, reflux (61%); (b) C₃H₇CHO, NaBH₃CN, CH₃OH, rt (40%).

the 6-ethylthio group in 2-amino-9-benzyl-6-ethylthio-8-hydroxypurine (**23**)¹⁸ using Raney Ni, followed by reductive alkylation using butyraldehyde afforded **25**. N⁶-ethyl analogue (**27**) containing a propylthio group at the 2-position was obtained by the reaction of 9-benzyl-8-hydroxy-2-propylthioadenine (**26**)¹⁸ with acetaldehyde in the presence of sodium cyanoborohydride in 69% yield (Scheme 6).

Results and Discussion

An in vitro assay for IFN-inducing activities of 2,8-disubstituted 9-benzyladenines (**5–10**, **14**, **16**, **18**, **22**) and 2,6-disubstituted 9-benzyl-8-hydroxypurines (**25**, **27**) synthesized above was performed by a typical method for determining IFN titer check.^{24,25} The activity is indicated by MEC (minimum effective concentration), which is the concentration of test compounds required for more than 0.9 IU/mL induction of IFN.

The in vitro IFN-inducing activities of 8-substituted 9-benzyl-2-butoxy or 2-butylaminoadenine derivatives (**5–10**, **14**, **16**, **18**, **22**) are summarized in Table 1. In the series of 2-butoxyadenines, 8-unsubstituted (**6**), chloro (**14**), bromo (**5**) and methyl (**8**) analogues, which possess no hydroxyl group at the 8-position, were 10 times more active than the original lead compound **1**. It was recently reported that 9-benzyl-8-mercaptoadenine, an 8-thio analogue of **1**, indicated an equivalent activity of




Scheme 6. Reagents and conditions: (a) CH₃CHO, NaBH₃CN, CH₃OH, 50 °C (69%).

Table 1. IFN-inducing activities of 2,8-disubstituted 9-benzyladenines

Compd	R ¹	R ²	MEC ^a (μM)
6	OC ₄ H ₉	H	1
14	OC ₄ H ₉	Cl	1
5	OC ₄ H ₉	Br	1
8	OC ₄ H ₉	CH ₃	1
7 ¹⁸	OC ₄ H ₉	OCH ₃	10
9	OC ₄ H ₉	SH	0.001
10	OC ₄ H ₉	SCH ₃	10
16	NHC ₄ H ₉	H	1
18	NHC ₄ H ₉	OCH ₃	> 10
22	NHC ₄ H ₉	SH	0.01
1	H	OH	10
2	OC ₄ H ₉	OH	0.001
4	NHC ₄ H ₉	OH	0.1
Imiquimod			1

^aMinimum effective concentration (mice spleen cells); concentration of compounds required for more than 0.9 IU/mL induction of IFN.

Table 2. IFN-inducing activities of 2,6-disubstituted 9-benzyl-8-hydroxypurines


Compd	R ¹	R ²	MEC ^a (μM)
25	NHC ₄ H ₉	H	1
27	SC ₃ H ₇	NHC ₂ H ₅	10
3	SC ₃ H ₇	NH ₂	0.01
4	NHC ₄ H ₉	NH ₂	0.1
Imiquimod			1

^aMinimum effective concentration (mice spleen cells): concentration of compounds required for more than 0.9 IU/mL induction of IFN.

1.¹⁷ Similarly, 2-butoxy-8-mercapto analogue (**9**) possessed activity equal to that of the corresponding 8-hydroxyl analogue **2** with MEC of 0.001 μM. However, *S*-methylation of **9** resulted in a drastic decrease of the activity (**10**, MEC = 10 μM). An analogous tendency was observed in the 2-butylamino series. 8-Unsubstituted analogue (**16**) showed the activity with MEC of 1 μM, which was equipotent with the 2-butoxy analogue **6**. 8-Methoxy analogue (**18**) was inactive (MEC = > 10 μM) unlike the case of 2-butoxy analogue **7**. Interestingly, the activity of 2-butylamino-8-mercapto analogue (**22**, MEC = 0.01 μM) was 10-fold more potent than that of the corresponding 8-hydroxyl analogue **4**.

As shown in Table 2, removal of the 6-amino group from 2-butylamino-8-hydroxyadenine **4** resulted in some reduction of IFN-inducing activity (**25**, MEC = 1 μM). On the other hand, the introduction of an ethyl group into the 6-amino group of 8-hydroxy-2-propylthioadenine **3** markedly decreased the activity (**27**, MEC = 10 μM).

Conclusion

In summary, we have synthesized 8-substituted 9-benzyladenines and 6-substituted 9-benzyl-8-hydroxypurines bearing an appropriate chain substituent such as a butoxy, propylthio or butylamino group at the 2-position and evaluated their IFN-inducing activities in order to investigate the structure–activity relationships of 2-substituted 9-benzyl-8-hydroxyadenines (**2–4**) and to explore highly active compounds. Among them, 2-butoxy-8-mercaptoadenine derivative (**9**), having an acidic proton at the 8-position like 8-hydroxyadenine **2**, emerged as having the most potent activity. The typical characteristics of the qualitative structure–activity relationship at the 8-position of the adenine nucleus are as follows: OH, SH > > H, halogene, CH₃ > OCH₃, SCH₃. It has been found that both of a 6-amino group and an 8-hydroxyl or thiol group are requisite to express excellent IFN-inducing activity and that the presence of the 2-butoxy group brings the most significant increase of the activity.

Experimental

Chemistry

Melting points were determined on a Yanagimoto melting-point apparatus and are uncorrected. UV absorption spectra were recorded on a Shimadzu 260 spectrophotometer. IR spectra were measured using Perkin Elmer 1640 FT-IR spectrometer. ¹H NMR spectra were recorded on a Jeol JNM EX-400 (400 MHz) spectrometer using DMSO-*d*₆ as a solvent. Chemical shifts are given in ppm (δ), coupling constants (*J*) are given in Hz, and splitting patterns are designated as follows: s, singlet; d, doublet; t, triplet; q, quartet; m, multiplet; br, broad; *, deuterium exchangeable. ¹³C NMR spectra were recorded on a Jeol JNM EX-400 (100 MHz) spectrometer using DMSO-*d*₆ as a solvent. Chemical shifts are given in ppm (δ) relative to internal solvent signals. Mass spectra were recorded on a JMS-SX 102A spectrometer. Elemental analyses were performed on Yanagimoto MT-3, and the results (C, H, N) were within ±0.3% of the theoretical values. Thin-layer chromatographic (TLC) analyses were carried out on 0.25 mm Silica Gel 60 F₂₅₄ plates (Art 5715, Merck). The silica gel used for column chromatography was Silica Gel 60 (230–400 mesh, Merck).

9-Benzyl-2-butoxyadenine (6). After two vacuum/H₂ cycles to remove air from the reaction flask, the mixture of **5**¹⁸ (100 mg, 0.27 mmol), 10% Pd/C (10% the weight of **5**) and Et₃N (44 μL, 0.32 mmol) in MeOH (5 mL) was hydrogenated at ambient pressure (balloon) and temperature for 2 h. The reaction mixture was filtered using a Celite cake and the filtrate was evaporated. The residue was chromatographed on silica gel (CHCl₃/MeOH = 100/1) to give **6** (75 mg, 94%). Mp 182–183 °C (washed with hexane) (lit.,²⁶ 174–175 °C); UV (EtOH) λ_{max} 268.8 nm (ε 13,200); IR (KBr) ν cm^{−1}: 3307, 3150, 1660, 1599, 1338; ¹H NMR δ 8.02 (1H, s, 8-H), 7.25–7.35 (5H, m, 9-Ph), 7.16 (2H, brs*, 6-NH₂), 5.25 (2H, s, 9-CH₂), 4.20 (2H, t, *J* = 6.6 Hz, 2-CH₂), 1.60–1.67 (2H, m, 2-CH₂), 1.34–1.43 (2H, m, 2-CH₂), 0.91 (3H, t, *J* = 7.3 Hz, 2-CH₃); ¹³C NMR δ 161.5, 156.7, 151.2, 139.3, 137.2, 128.6, 127.6, 115.0, 65.7, 45.9, 30.6, 18.7, 13.7; MS (EI) *m/z* 297 (M⁺), 241, 240, 91; HRMS (EI) calcd for C₁₆H₁₉N₅O (M⁺): 297.1590. Found: 297.1595; Anal. calcd for C₁₆H₁₉N₅O: C, 64.63; H, 6.44; N, 23.55. Found: C, 64.55; H, 6.38; N, 23.42.

9-Benzyl-2-butoxy-8-methyladenine (8). A mixture of **5**¹⁸ (100 mg, 0.27 mmol), 1 M hexane solution of AlMe₃ (0.53 mL, 0.53 mmol), PdCl₂ (2.4 mg, 0.01 mmol) and Ph₃P (7.0 mg, 0.03 mmol) in dry THF (5 mL) was refluxed under Ar atmosphere for 10 h. After evaporation, the residue was triturated with CHCl₃ (10 mL) and the resulting suspension was filtered using a Celite cake. The filtrate was partitioned between CHCl₃ (10 mL) and H₂O (10 mL), whose organic layer was washed with brine (10 mL) and dried over MgSO₄. After filtration and evaporation, the residue was chromatographed on silica gel (CHCl₃/MeOH = 200/1), which was triturated with hexane (2 mL) to give **8** (80 mg, 96%). Mp 135–136 °C (washed with hexane); UV (EtOH) λ_{max} 269.4 nm (ε 13,600); IR (KBr) ν cm^{−1}: 3313, 3148, 2958,

1654, 1600, 1465, 1342; ^1H NMR δ 7.18–7.34 (5H, m, 9-Ph), 7.06 (2H, brs*, 6-NH₂), 5.24 (2H, s, 9-CH₂), 4.19 (2H, t, J =6.6 Hz, 2-CH₂), 2.34 (3H, s, 8-CH₃), 1.60–1.67 (2H, m, 2-CH₂), 1.34–1.43 (2H, m, 2-CH₂), 0.90 (3H, t, J =7.3 Hz, 2-CH₃); ^{13}C NMR δ 161.0, 155.8, 152.4, 146.8, 136.9, 128.7, 127.5, 127.0, 113.7, 65.7, 44.7, 30.7, 18.7, 13.7; MS (EI) m/z 311 (M^+), 282, 268, 255, 240, 91; HRMS (EI) calcd for $\text{C}_{17}\text{H}_{21}\text{N}_5\text{O}$ (M^+): 311.1746. Found: 311.1754; Anal. calcd for $\text{C}_{17}\text{H}_{21}\text{N}_5\text{O}$: C, 65.57; H, 6.80; N, 22.49. Found: C, 65.34; H, 6.71; N, 22.31.

9-Benzyl-2-butoxy-8-thioadenine (9). A mixture of **5**¹⁸ (200 mg, 0.53 mmol) and thiourea (81 mg, 1.06 mmol) in dry EtOH (8 mL) was refluxed under Ar atmosphere for 24 h. After evaporation, the residue was partitioned between AcOEt (20 mL) and H₂O (20 mL). The organic layer was washed with brine (20 mL) and dried over MgSO₄. After filtration, the residue was chromatographed on silica gel (CHCl₃/MeOH=50/1) to give **9** (151 mg, 86%). Mp 268–269 °C (recrystallized from EtOH); UV (EtOH) λ_{max} 241.2 nm (ϵ 15,000), 267.8 nm (ϵ 7600), 314.8 nm (ϵ 28,000); IR (KBr) ν cm⁻¹: 3396, 3171, 1678, 1616, 1486, 1354; ^1H NMR δ 12.18 (1H, s*, 8-SH), 7.23–7.38 (5H, m, 9-Ph), 6.85 (2H, brs*, 6-NH₂), 5.26 (2H, s, 9-CH₂), 4.17 (2H, t, J =6.3 Hz, 2-CH₂), 1.58–1.65 (2H, m, 2-CH₂), 1.32–1.41 (2H, m, 2-CH₂), 0.89 (3H, t, J =7.1 Hz, 2-CH₃); ^{13}C NMR δ 166.0, 161.3, 150.9, 148.6, 136.3, 128.3, 127.8, 127.4, 102.6, 66.1, 45.0, 30.4, 18.6, 13.6; MS (EI) m/z 329 (M^+), 273, 240, 182, 91; HRMS (EI) calcd for $\text{C}_{16}\text{H}_{19}\text{N}_5\text{OS}$ (M^+): 329.1310. Found: 329.1304; Anal. calcd for $\text{C}_{16}\text{H}_{19}\text{N}_5\text{OS}$: C, 58.34; H, 5.81; N, 21.26. Found: C, 58.28; H, 5.74; N, 21.34.

9-Benzyl-2-butoxy-8-methylthioadenine (10). A mixture of **9** (100 mg, 0.30 mmol) and K₂CO₃ (44 mg, 0.32 mmol) in dry DMF (6 mL) was stirred under Ar atmosphere at room temperature for 0.5 h. To the mixture was added methyl iodide (23 μL , 0.36 mmol) and the mixture was stirred at room temperature for 3 h. The solvent was removed under reduced pressure and the residue was triturated with H₂O (5 mL). The resulting suspension was neutralized with 10% NaHSO₄ solution and extracted with AcOEt (20 mL). The organic layer was washed with brine (20 mL) and dried over MgSO₄. After filtration, the solvent was evaporated and the residue was chromatographed on silica gel (CHCl₃/MeOH=200/1) to give **10** (87 mg, 83%); mp 158–159 °C (recrystallized from EtOH); UV (EtOH) λ_{max} 282.4 nm (ϵ 16,700); IR (KBr) ν cm⁻¹: 3490, 3101, 1641, 1595, 1354, 1265, 1194, 732; ^1H NMR δ 7.22–7.34 (5H, m, 9-Ph), 7.10 (2H, s*, 6-NH₂), 5.16 (2H, s, 9-CH₂), 4.19 (2H, t, J =6.6 Hz, 2-CH₂), 2.61 (3H, s, 8-CH₃), 1.60–1.67 (2H, m, 2-CH₂), 1.34–1.43 (2H, m, 2-CH₂), 0.90 (3H, t, J =7.3 Hz, 2-CH₃); ^{13}C NMR δ 160.9, 154.9, 153.3, 146.4, 136.3, 128.6, 127.6, 127.3, 115.1, 65.8, 45.2, 30.6, 18.7, 14.3, 13.7; MS (EI) m/z 343 (M^+), 287, 196, 91; HRMS (EI) calcd for $\text{C}_{17}\text{H}_{21}\text{N}_5\text{OS}$ (M^+): 343.1467. Found: 343.1462; Anal. calcd for $\text{C}_{17}\text{H}_{21}\text{N}_5\text{OS}$: C, 59.45; H, 6.16; N, 20.39. Found: C, 59.42; H, 6.22; N, 20.31.

5-Amino-1-benzyl-2-chloro-4-cyanoimidazole (12). To a solution of **11**²² (700 mg, 3.53 mmol) in dry THF (15 mL) was added *N*-chlorosuccinimide (519 mg, 3.89 mmol) in dry THF (15 mL), and the reaction mixture was stirred under Ar atmosphere at room temperature for 10 h. After evaporation, the resulting solid was partitioned between AcOEt (50 mL) and saturated NaHCO₃ (50 mL) solution. The organic layer was washed with brine (30 mL) and dried over MgSO₄. After filtration, the solvent was evaporated off, and the solidified product was chromatographed on silica gel (CHCl₃/MeOH=50/1) to give **12** (713 mg, 87%); mp 206–208 °C (recrystallized from benzene); UV (EtOH) λ_{max} 249.0 nm (ϵ 14,000); IR (KBr) ν cm⁻¹: 3334, 3179, 2222, 1650, 1596, 1502, 1195, 725; ^1H NMR δ 7.28–7.38 (3H, m, 1-Ph), 7.13 (2H, d, J =7.8 Hz, 1-Ph), 6.69 (2H, s*, 5-NH₂), 5.12 (2H, s, 1-CH₂); ^{13}C NMR δ 149.2, 135.2, 128.7, 127.7, 126.5, 124.7, 116.2, 88.8, 45.8; MS (EI) m/z 234 ($\text{M}^+ + 2$), 232 (M^+), 91; HRMS (EI) calcd for $\text{C}_{11}\text{H}_9\text{ClN}_4$ (M^+): 232.0516. Found: 232.0512; anal. calcd for $\text{C}_{11}\text{H}_9\text{ClN}_4$: C, 56.78; H, 3.90; N, 24.08. Found: C, 56.91; H, 4.00; N, 24.13.

9-Benzyl-8-chloro-2-hydroxyadenine (13). A mixture of **12** (650 mg, 2.79 mmol) and urea (1.68 g, 27.94 mmol) was heated under Ar atmosphere at 160 °C for 24 h. An additional amount of urea (1.68 g, 27.94 mmol) was added to the reaction mixture and the resulting mixture was heated at 160 °C for 12 h. The residue was triturated with H₂O (20 mL) and the resulting precipitate was filtered to give **13** (604 mg, 78%); mp > 300 °C (washed with hot MeOH and hot H₂O); ^1H NMR δ 10.63 (1H, brs*, 2-OH), 7.63 (2H, brs*, 6-NH₂), 7.22–7.36 (5H, m, 9-Ph), 5.13 (2H, s, 9-CH₂); MS (EI) m/z 277 ($\text{M}^+ + 2$), 275 (M^+), 240, 91; HRMS (EI) calcd for $\text{C}_{12}\text{H}_{10}\text{ClN}_5\text{O}$ (M^+): 275.0574. Found: 275.0567.

9-Benzyl-2-butoxy-8-chloroadenine (14). A mixture of **13** (400 mg, 1.45 mmol) and K₂CO₃ (602 mg, 4.35 mmol) in dry DMF (8 mL) was stirred under Ar atmosphere at room temperature for 1 h. To the mixture was added butyl bromide (0.47 mL, 4.35 mmol) and the mixture was stirred at room temperature for 2 days. The solvent was removed under reduced pressure and the residue was triturated with H₂O (15 mL). The resulting suspension was neutralized with 10% NaHSO₄ solution and extracted with AcOEt (30 mL). The organic layer was washed with brine (30 mL) and dried over MgSO₄. After filtration, the solvent was evaporated and the residue was chromatographed on silica gel (CHCl₃). The obtained oily product was solidified with ether (3 mL) and filtered to give **14** (319 mg, 66%); mp 144–145 °C (washed with hexane and MeOH); UV (EtOH) λ_{max} 270.6 nm (ϵ 14,600); IR (KBr) ν cm⁻¹: 3488, 3114, 2958, 1639, 1594, 1348, 731; ^1H NMR δ 7.37 (2H, brs*, 6-NH₂), 7.24–7.36 (5H, m, 9-Ph), 5.25 (2H, s, 9-CH₂), 4.21 (2H, t, J =6.6 Hz, 2-CH₂), 1.61–1.68 (2H, m, 2-CH₂), 1.34–1.43 (2H, m, 2-CH₂), 0.90 (3H, t, J =7.3 Hz, 2-CH₃); ^{13}C NMR δ 161.6, 155.8, 152.0, 135.9, 134.1, 128.7, 127.8, 127.2, 113.7, 66.0, 45.6, 30.6, 18.7, 13.7; MS (EI) m/z 333 ($\text{M}^+ + 2$), 331 (M^+), 275, 91; HRMS (EI) calcd for $\text{C}_{16}\text{H}_{18}\text{ClN}_5\text{O}$ (M^+): 331.1200. Found: 331.1208; Anal. calcd for

C₁₆H₁₈ClN₅O: C, 57.92; H, 5.47; N, 21.11. Found: C, 57.90; H, 5.50; N, 21.10.

2-Amino-9-benzyladenine (15). To a solution of Na (0.65 g, 28.25 mmol) in dry EtOH (30 mL) was added guanidine hydrochloride (3.37 g, 35.31 mmol) and the mixture was stirred at room temperature for 5 min. The resulting precipitate was filtered off and the filtrate was refluxed with **11**²² (0.70 g, 3.35 mmol) under Ar atmosphere for 10 h. The solvent was removed under reduced pressure and the residue was chromatographed on silica gel (CHCl₃/MeOH = 50/1) to give **15** (840 mg, 99%), which was used for the next reaction without further purification: mp. 192–193 °C (lit.²⁷ 180–181 °C); ¹H NMR δ 7.77 (1H, s, 8-H), 7.20–7.34 (5H, m, 9-Ph), 6.69 and 5.80 (each 2H, each s*, 2-NH₂ and 6-NH₂), 5.18 (2H, s, 9-CH₂); ¹³C NMR δ 160.5, 156.2, 151.8, 137.7, 137.4, 128.6, 127.4, 127.1, 113.1, 45.4.

9-Benzyl-2-butylaminoadenine (16). To a suspension of **15** (100 mg, 0.42 mmol) and NaBH₃CN (157 mg, 2.50 mmol) in MeOH (5 mL) was added butyraldehyde (0.30 mL, 3.33 mmol) and the mixture was stirred under Ar atmosphere at room temperature for 2 days. After evaporation, the residue was chromatographed on silica gel (CHCl₃/MeOH = 100/1) to give **16** (104 mg, 84%): mp 147–148 °C (washed with hexane); UV (EtOH) λ_{max} 259.0 nm (ε 9900), 289.4 nm (ε 9500); IR (KBr) ν cm⁻¹: 3322, 2956, 1599, 1539, 1482, 721; ¹H NMR δ 7.77 (1H, s, 8-H), 7.23–7.33 (5H, m, 9-Ph), 6.60 (2H, brs*, 6-NH₂), 6.19 (1H, t*, J = 6.7 Hz, 2-NH), 5.16 (2H, s, 9-CH₂), 3.22 (2H, q, J = 6.7 Hz, 2-CH₂), 1.43–1.51 (2H, m, 2-CH₂), 1.25–1.34 (2H, m, 2-CH₂), 0.87 (3H, t, J = 7.3 Hz, 2-CH₃); ¹³C NMR δ 159.6, 155.9, 151.7, 137.6, 137.1, 128.5, 127.6, 127.5, 113.0, 45.6, 40.7, 31.5, 19.7, 13.9; MS (EI) m/z 296 (M⁺), 267, 253, 240, 91; HRMS (EI) calcd for C₁₆H₂₀N₆ (M⁺): 296.1749. Found: 296.1765; Anal. calcd for C₁₆H₂₀N₆·1/8H₂O: C, 64.35; H, 6.84; N, 28.14. Found: C, 64.40; H, 6.77; N, 28.08.

2-Amino-9-benzyl-8-methoxyadenine (17). The reaction of 5-amino-1-benzyl-2-bromo-4-cyanoimidazole¹⁸ with guanidine under the same conditions as those for the preparation of **15** gave 2-amino-9-benzyl-8-bromoade-nine (for 9 h): Yield 90%; mp 274–275 °C (washed with ether); UV (EtOH) λ_{max} 260.2 nm (ε 9800), 286.0 nm (ε 12700); IR (KBr) ν cm⁻¹: 3466, 3310, 3191, 1595, 1473; ¹H NMR δ 7.25–7.35 (3H, m, 9-Ph), 7.16 (2H, d, J = 6.8 Hz, 9-Ph), 6.88 (2H, brs*, 2-NH₂ or 6-NH₂), 5.96 (2H, s*, 2-NH₂ or 6-NH₂), 5.16 (2H, s, 9-CH₂); ¹³C NMR δ 160.5, 155.1, 153.1, 136.4, 128.7, 127.5, 126.7, 121.2, 113.4, 45.8; MS (EI) m/z 320 (M⁺ + 2), 318 (M⁺), 239, 91; HRMS (EI) calcd for C₁₂H₁₁BrN₆ (M⁺): 318.0229. Found: 318.0233; Anal. calcd for C₁₂H₁₁BrN₆: C, 45.16; H, 3.47; N, 26.33. Found: C, 45.09; H, 3.43; N, 26.18. A mixture of 2-amino-9-benzyl-8-bromoade-nine (459 mg, 1.44 mmol) in MeOH (10 mL) and 1 N NaOH solution (10 mL) was refluxed for 2 days. After evaporation, the residue was triturated with H₂O (20 mL) and the mixture was neutralized with 10% NaHSO₄ solution. The resulting mixture was extracted with AcOEt (30 mL) and the organic layer was

washed with brine (20 mL) and dried over MgSO₄. After filtration, the solvent was removed under reduced pressure, and the product was chromatographed on silica gel (CHCl₃/MeOH = 100/1) to give **17** (271 mg, 70%): mp 239–241 °C (washed with ether); UV (EtOH) λ_{max} 251.6 nm (ε 10,600), 283.0 nm (ε 9600); IR (KBr) ν cm⁻¹: 3486, 3322, 3182, 1604, 1401, 1337, 1242; ¹H NMR δ 7.23–7.33 (3H, m, 9-Ph), 7.16 (2H, d, J = 7.3 Hz, 9-Ph), 6.34 and 5.64 (each 2H, each s*, 2-NH₂ and 6-NH₂), 4.97 (2H, s, 9-CH₂), 3.97 (3H, s, 8-CH₃); ¹³C NMR δ 159.2, 154.0, 152.4, 151.5, 137.1, 128.5, 127.3, 126.8, 107.7, 56.5, 43.3; MS (EI) m/z 270 (M⁺), 255, 179, 91; HRMS (EI) calcd for C₁₃H₁₄N₆O (M⁺): 270.1229. Found: 270.1224; anal. calcd for C₁₃H₁₄N₆O: C, 57.77; H, 5.22; N, 31.09. Found: C, 57.89; H, 5.23; N, 30.93.

9-Benzyl-2-butylamino-8-methoxyadenine (18). Compound **18** was prepared by the reaction of **17** with butyraldehyde in the presence of NaBH₃CN according to the synthetic procedure for the preparation of **16** (for 2 days): Yield 85%; mp 134–135 °C (recrystallized from toluene); UV (EtOH) λ_{max} 253.6 nm (ε 11,700), 288.0 nm (ε 7800); IR (KBr) ν cm⁻¹: 3332, 3197, 2932, 1608, 1528, 1399; ¹H NMR δ 7.22–7.33 (5H, m, 9-Ph), 6.27 (2H, s*, 6-NH₂), 6.04 (1H, t*, J = 6.3 Hz, 2-NH), 4.96 (2H, s, 9-CH₂), 3.98 (3H, s, 8-CH₃), 3.19 (2H, q, J = 6.3 Hz, 2-CH₂), 1.42–1.49 (2H, m, 2-CH₂), 1.25–1.34 (2H, m, 2-CH₂), 0.86 (3H, t, J = 7.3 Hz, 2-CH₃); ¹³C NMR δ 158.5, 153.8, 152.2, 151.4, 137.1, 128.4, 127.3, 127.1, 107.5, 56.4, 43.4, 40.7, 31.5, 19.7, 13.8; MS (EI) m/z 326 (M⁺), 297, 283, 270, 91; HRMS (EI) calcd for C₁₇H₂₂N₆O (M⁺): 326.1855. Found: 326.1862.

5-Amino-2-benzylamino-4-cyanothiazole (19). To a suspension of aminomalononitrile *p*-toluenesulfonate (2.00 g, 7.90 mmol) in dry THF (20 mL) was added *N,N*-diisopropylethylamine (1.10 mL, 6.32 mmol) and the mixture was stirred under Ar atmosphere at room temperature for 5 min. To the solution was added benzyl isothiocyanate (2.09 mL, 15.79 mmol) in dry THF (20 mL) and the mixture was stirred at 40 °C for 72 h. The solvent was removed under reduced pressure, and the residue was partitioned between AcOEt (100 mL) and H₂O (100 mL). The organic layer was washed with brine (50 mL) and dried over MgSO₄. The solvent was evaporated and the residue was chromatographed on silica gel (CHCl₃) to give **19** (1.57 g, 86%): mp 143–145 °C (washed with hexane); UV (EtOH) λ_{max} 252.2 nm (ε 7600), 305.0 nm (ε 7300); IR (KBr) ν cm⁻¹: 3410, 3300, 3198, 2212, 1612, 1547, 1213, 699; ¹H NMR δ 7.54 (1H, t*, J = 5.9 Hz, 2-NH), 7.22–7.34 (5H, m, 2-Ph), 6.45 (2H, s*, 5-NH₂), 4.31 (2H, d, J = 5.9 Hz, 2-CH₂); ¹³C NMR δ 153.6, 153.4, 139.2, 128.3, 127.4, 126.9, 116.9, 95.8, 46.7; MS (EI) m/z 230 (M⁺), 91; HRMS (EI) calcd for C₁₁H₁₀N₄S (M⁺): 230.0626. Found: 230.0633; Anal. calcd for C₁₁H₁₀N₄S: C, 57.37; H, 4.38; N, 24.33. Found: C, 57.21; H, 4.23; N, 24.10.

5-Amino-1-benzyl-4-cyano-2-mercaptoimidazole (20). The suspension of **19** (500 mg, 2.17 mmol) in 5% Na₂CO₃ solution (15 mL) was refluxed for 2 h. The mixture was neutralized with 1 N HCl solution and the pre-

cipitated solid was collected, which was chromatographed on silica gel (CHCl₃/MeOH = 50:1) to give **20** (420 mg, 84%); mp 280–283 °C (recrystallized from MeOH); UV (EtOH) λ_{max} 289.4 nm (ϵ 17,600); IR (KBr) ν cm⁻¹: 3329, 3183, 2216, 1656, 1468, 1334, 1171, 696; ¹H NMR δ 12.39 (1H, s*, 2-SH), 7.25–7.33 (5H, m, 1-Ph), 6.77 (2H, s*, 5-NH₂), 5.21 (2H, s, 1-CH₂); ¹³C NMR δ 160.0, 147.1, 135.6, 128.3, 127.3, 127.0, 113.1, 75.1, 45.1; MS (EI) m/z 230 (M⁺), 91; HRMS (EI) calcd for C₁₁H₁₀N₄S (M⁺): 230.0626. Found: 230.0619; Anal. calcd for C₁₁H₁₀N₄S: C, 57.37; H, 4.38; N, 24.33. Found: C, 57.39; H, 4.58; N, 24.11.

2-Amino-9-benzyl-8-mercaptoadenine (21). Method A. Compound **21** was prepared by the reaction of **20** with guanidine according to the synthetic procedure for the preparation of **15** in 69% yield (for 2 days).

Method B. To a solution of Na (100 mg, 4.34 mmol) in dry EtOH (3 mL) was added guanidine hydrochloride (415 mg, 4.34 mmol) and the mixture was stirred under Ar atmosphere at room temperature for 5 min. To the resulting mixture was added **19** (100 mg, 0.43 mmol) in dry EtOH (2 mL) and the mixture was refluxed for 17 h. After evaporation, the residue was triturated with H₂O (10 mL). The mixture was neutralized with AcOH and extracted with AcOEt (20 mL). The organic layer was washed with brine (10 mL) and dried over MgSO₄. The solvent was evaporated to give **21** (90 mg, 76%); mp 290–292 °C; UV (EtOH) λ_{max} 268.4 nm (ϵ 9100), 315.8 nm (ϵ 22,600); IR (KBr) ν cm⁻¹: 3415, 1621, 1476, 1437; ¹H NMR δ 11.93 (1H, s*, 8-SH), 7.23–7.32 (5H, m, 9-Ph), 6.41 and 6.01 (each 2H, each s*, 2-NH₂ and 6-NH₂), 5.21 (2H, s, 9-CH₂); ¹³C NMR δ 164.4, 160.4, 151.2, 148.3, 136.5, 128.2, 127.3, 127.1, 100.1, 44.7; MS (EI) m/z 272 (M⁺), 239, 181, 154, 91; HRMS (EI) calcd for C₁₂H₁₂N₆S (M⁺): 272.0844. Found: 272.0851.

9-Benzyl-2-butylamino-8-mercaptoadenine (22). Compound **22** was prepared by the reaction of **21** with butyraldehyde in the presence of NaBH₃CN according to the synthetic procedure for the preparation of **16** (for 2 days): Yield 72%; mp 272–274 °C (recrystallized from EtOH); UV (EtOH) λ_{max} 271.2 nm (ϵ 12,100), 321.2 nm (ϵ 23,100); IR (KBr) ν cm⁻¹: 3370, 3129, 1625, 1537, 1460, 1369, 696; ¹H NMR δ 11.89 (1H, s*, 8-SH), 7.23–7.37 (5H, m, 9-Ph), 6.48 (1H, brt*, J = 6.5 Hz, 2-NH), 6.39 (2H, brs*, 6-NH₂), 5.20 (2H, s, 9-CH₂), 3.17 (2H, q, J = 6.5 Hz, 2-CH₂), 1.40–1.47 (2H, m, 2-CH₂), 1.23–1.32 (2H, m, 2-CH₂), 0.85 (3H, t, J = 7.1 Hz, 2-CH₃); ¹³C NMR δ 164.1, 159.5, 151.1, 148.2, 136.7, 128.2, 127.8, 127.3, 99.9, 44.8, 40.6, 31.3, 19.7, 13.8; MS (EI) m/z 328 (M⁺), 285, 91; HRMS (EI) calcd for C₁₆H₂₀N₆S (M⁺): 328.1470. Found: 328.1462; anal. calcd for C₁₆H₂₀N₆S: C, 58.51; H, 6.14; N, 25.59. Found: C, 58.61; H, 6.15; N, 25.64.

2-Amino-9-benzyl-8-hydroxypurine (24). To a suspension of **23**¹⁸ (116 mg, 0.38 mmol) in MeOH (10 mL) and 28% NH₄OH solution (2 mL) was added Raney Ni (1 mL of suspension in H₂O) and the mixture was refluxed for 9 h. After removal of the catalyst by filtration using

Celite cake, the filtrate was concentrated in vacuo. The residue was chromatographed on silica gel (CHCl₃/MeOH = 40:1) to give **24** (56 mg, 61%); mp 268–269 °C; UV (EtOH) λ_{max} 314.0 nm (ϵ 8300); IR (KBr) ν cm⁻¹: 3462, 1720, 1641, 1453; ¹H NMR δ 10.80 (1H, s*, 8-OH), 7.74 (1H, s, 6-H), 7.24–7.34 (5H, m, 9-Ph), 6.20 (2H, s*, 2-NH₂), 4.87 (2H, s, 9-CH₂); ¹³C NMR δ 159.2, 153.1, 151.2, 136.8, 134.5, 128.5, 127.4, 127.1, 113.5, 42.0; MS (EI) m/z 241 (M⁺), 150, 91; HRMS (EI) calcd for C₁₂H₁₁N₅O (M⁺): 241.0964. Found: 241.0957.

9-Benzyl-2-butylamino-8-hydroxypurine (25). Compound **25** was prepared by the reaction of **24** with butyraldehyde in the presence of NaBH₃CN according to the synthetic procedure for the preparation of **16** (for 2 days): Yield 40%; mp 224–225 °C (washed with ether); UV (EtOH) λ_{max} 227.4 nm (ϵ 19,600), 324.2 nm (ϵ 7900); IR (KBr) ν cm⁻¹: 3354, 2957, 1708, 1639, 1540, 1461, 1132, 698; ¹H NMR δ 10.75 (1H, s*, 8-OH), 7.77 (1H, s, 6-H), 7.23–7.33 (5H, m, 9-Ph), 6.72 (1H, t*, J = 6.3 Hz, 2-NH), 4.86 (2H, s, 9-CH₂), 3.18 (2H, t, J = 6.3 Hz, 2-CH₂), 1.42–1.49 (2H, m, 2-CH₂), 1.24–1.33 (2H, m, 2-CH₂), 0.86 (3H, t, J = 7.3 Hz, 2-CH₃); ¹³C NMR δ 158.3, 153.1, 151.1, 136.9, 134.4, 128.5, 127.4, 113.2, 42.0, 40.8, 31.2, 19.7, 13.8; MS (EI) m/z 297 (M⁺), 268, 254, 241, 91; HRMS (EI) calcd for C₁₆H₁₉N₅O (M⁺): 297.1590. Found: 297.1587; Anal. calcd for C₁₆H₁₉N₅O: C, 64.63; H, 6.44; N, 23.55. Found: C, 64.36; H, 6.44; N, 23.35.

9-Benzyl-N⁶-ethyl-8-hydroxy-2-propylthioadenine (27). To a suspension of **26**¹⁸ (100 mg, 0.32 mmol) and NaBH₃CN (120 mg, 1.90 mmol) in dry MeOH (20 mL) was added acetaldehyde (0.46 mL, 8.24 mmol) and the mixture was stirred under Ar atmosphere at 50 °C for 8 days. After evaporation, the residue was chromatographed on silica gel (CHCl₃/MeOH = 100:1) to give **27** (75 mg, 69%); mp 214–215 °C (washed with ether); UV (EtOH) λ_{max} 229.2 nm (ϵ 20,700), 287.2 nm (ϵ 16,600); IR (KBr) ν cm⁻¹: 3348, 2965, 1701, 1636, 1452, 1345, 701; ¹H NMR δ 10.01 (1H, s*, 8-OH), 7.23–7.33 (5H, m, 9-Ph), 6.55 (1H, brt*, J = 5.4 Hz, 6-NH), 4.86 (2H, s, 9-CH₂), 3.37–3.43 (2H, m, 6-CH₂), 2.97 (2H, t, J = 7.3 Hz, 2-CH₂), 1.58–1.67 (2H, m, 2-CH₂), 1.16 (3H, t, J = 7.1 Hz, 6-CH₃), 0.93 (3H, t, J = 7.1 Hz, 2-CH₃); ¹³C NMR δ 161.5, 151.7, 147.3, 146.0, 137.1, 128.5, 127.43, 127.37, 100.3, 42.4, 34.9, 32.2, 22.8, 14.9, 13.3; MS (EI) m/z 343 (M⁺), 328, 310, 91; HRMS (EI) calcd for C₁₇H₂₁N₅OS (M⁺): 343.1467. Found: 343.1463; Anal. calcd for C₁₇H₂₁N₅OS: C, 59.45; H, 6.16; N, 20.39. Found: C, 59.18; H, 6.15; N, 20.14.

Biology

IFN induction in mouse splenocyte cultures. Male C3H/HeJ mice (Clea Japan Inc.) aged 8 weeks were sacrificed, spleens were removed from 6 mice. Spleens were meshed in phosphate buffered saline (PBS) and filtered through nylon mesh. The cell suspension was freed of erythrocytes by hypotonic treatment with 0.2% NaCl solution, and washed twice with PBS. Splenocytes were resuspended at a concentration of 2×10^6 cells/mL in MEM supplemented with 5% fetal calf serum, 100 U/

mL of penicillin, and 100 µg/mL of streptomycin. The test compounds were dissolved in DMSO and diluted to 500-fold with supplemented MEM.

Above splenocytes suspension (0.5 mL) and various concentration of the test compounds solution (0.5 mL) were mixed in 24-well plates, and cultured in a humidified 5% CO₂/95% air atmosphere at 37 °C for 18 h. Supernatants were then collected, filter sterilized, and stored at –80 °C until they were analyzed for IFN.

IFN analysis. Mouse IFN titer in supernatants of splenocytes was quantitated by measuring its antiviral activity in a bioassay using mouse L929 cell monolayers challenged with vesicular stomatitis virus.²⁴ Results are expressed as IFN IU/mL in terms of the international mouse IFN standard²⁵ obtained from the National Institute of Health, Bethesda, MD, USA.

Acknowledgements

The authors thank Dr. H. Hayashi and his co-workers, Japan Energy Corporation for measurements of IFN-inducing activities.

References and Notes

- World Health Organization. *Weekly Epidemiological Record*. **1999**, N-49.
- Damen, M.; Bresters, D. In *Hepatitis C Virus: Current Studies in Hematology and Blood Transfusion* No 62; Reesink, H. W., Ed. Karger Publishers: Basel, 1998.
- Rönnblom, L. E.; Tiensuu Janson, E.; Perers, A.; Öberg, K. E.; Alm, G. V. *Clin. Exp. Immunol.* **1992**, *89*, 330.
- Wierenga, W. *Annu. Rep. Med. Chem.* **1982**, *17*, 151.
- Krueger, R. F.; Mayer, G. D. *Science* **1970**, *169*, 1213.
- Siminoff, P.; Bernard, A. M.; Hursky, V. S.; Price, K. E. *Antimicrob. Agents Chemother.* **1973**, *3*, 742.
- Gláz, E. T.; Szolgay, E.; Stöger, I.; Tálas, M. *Antimicrob. Agents Chemother.* **1973**, *3*, 537.
- Hoffman, W. W.; Korst, J. J.; Niblack, J. F.; Cronin, T. H. *Antimicrob. Agents Chemother.* **1973**, *3*, 498.
- Nichol, F. R.; Weed, S. D.; Underwood, G. E. *Antimicrob. Agents Chemother.* **1976**, *9*, 433.
- Tamm, I.; Sehgal, P. B. *J. Exp. Med.* **1977**, *145*, 344.
- Taylor, J. L.; Schoenherr, C. K.; Grossberg, S. E. *Antimicrob. Agents Chemother.* **1980**, *18*, 20.
- Wierenga, W.; Skulnick, H. I.; Stringfellow, D. A.; Weed, S. D.; Renis, H. E.; Eidson, E. E. *J. Med. Chem.* **1980**, *23*, 237.
- Weeks, C. E.; Reiter, M. J. *J. Invest. Dermatol.* **1989**, *93*, 584.
- Dockrell, D. H.; Kinghorn, G. R. *J. Antimicrob. Chemother.* **2001**, *48*, 751.
- Weeks, C. E.; Gibson, S. J. *J. Interferon Res.* **1994**, *14*, 81.
- Tomai, M. A.; Gibson, S. J.; Imbertson, L. M.; Miller, R. L.; Myhre, P. E.; Reiter, M. J.; Wagner, T. L.; Tamulinas, C. B.; Beaurline, J. M.; Gerster, J. F.; Horton, V. L. *Antiviral Res.* **1995**, *28*, 253.
- Hirota, K.; Kazaoka, K.; Niimoto, I.; Kumihara, H.; Sajiki, H.; Isobe, Y.; Takaku, H.; Tobe, M.; Ogita, H.; Ogino, T.; Ichii, S.; Kurimoto, A.; Kawakami, H. *J. Med. Chem.* **2002**, *45*, 5419.
- Hirota, K.; Kazaoka, K.; Niimoto, I.; Sajiki, H. *Org. Biomol. Chem.* **2003**, *1*, 1354.
- Kazaoka, K.; Sajiki, H.; Hirota, K. *Chem. Pharm. Bull.* **2003**, *51*, 608.
- Hirota, K.; Kitade, Y.; Kanbe, Y.; Maki, Y. *J. Org. Chem.* **1992**, *57*, 5268.
- Lin, T.-S.; Cheng, J.-C.; Ishiguro, K.; Sartorelli, A. C. *J. Med. Chem.* **1985**, *28*, 1194.
- (a) Booth, B. L.; Carpenter, R. A.; Morlock, G.; Mahmood, Z.; Pritchard, R. B. *Synthesis* **2001**, 2393. (b) Sen, A. K.; Ray, S. *Indian J. Chem.* **1976**, *14B*, 346.
- Ring-transformation of 5-amino-2-benzylamino-4-carbamoylthiazole into the corresponding 2-mercaptoimidazole was previously reported. See: Sen, A. K.; Ray, S. *Indian J. Chem.* **1976**, *14B*, 351.
- Watanabe, Y.; Kawade, Y. In *Lymphokines and Interferons: A Practical Approach*; Clemens, M. J.; Morris, A. G.; Gearing, A. J. H., Eds.; IRL Press: Oxford, 1987; pp 1–14.
- Pestka, S. *Method in Enzymology*, Pestka, S., Ed.; Academic Press: New York, 1986; Vol. 119, pp 14–23.
- Naito, T.; Nakagawa, S.; Okita, T.; Yamashita, H.; Yamasaki, T.; Kamei, H.; Tomatsu, K.; Imanishi, H.; Kawaguchi, H. *Chem. Pharm. Bull.* **1982**, *30*, 2011.
- Montgomery, J. A.; Hewson, K. *J. Am. Chem. Soc.* **1960**, *82*, 463.